NEW YORK (GenomeWeb) – MDNA Life Sciences announced today an exclusive licensing agreement with Laboratory Corporation of America for a liquid biopsy-based noninvasive test for patients who may have prostate cancer.

Under the terms of the deal, which covers the US, LabCorp will be able to use MDNA's technology to develop and commercialize a test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.